Private network · Publisher approval required

Private Telehealth & Peptide Affiliate Programs

Find telehealth affiliate programs by the care topic your audience is researching. Explore the categories below, then apply for publisher access through MarketHealth.

Programs are available through private publisher review. Advertiser names, payouts, campaign materials and tracking links are shared only after the relevant approval. One publisher application starts the conversation; each campaign has its own requirements.

Apply for Private Publisher AccessBrowse Telehealth Categories

Weight management Affiliate Programs

Men’s health Affiliate Programs

Women’s health Affiliate Programs

Hair & skin Affiliate Programs

Clinical services Affiliate Programs

Peptides & longevity Affiliate Programs

Peptide access stays specific to the campaign

Peptide medicines, compounded preparations and research products have different requirements. This directory does not advertise research-use-only products as treatments or imply that a trending substance is available through a permissible clinical program.

NAD+ appears as an adjacent clinical-wellness topic; it is not a peptide.

Apply for Private Publisher AccessBrowse Telehealth Categories

This is a topic directory for prospective publishers, not a ranking by sales, search volume or payout. Clinical decisions belong to licensed healthcare professionals.

Complete requested topic list · 31 entries

Peptide Affiliate Programs & Publisher Information

All 31 requested peptide and related telehealth names are listed below. Private program, publisher-review and investigational information pages have different scopes. A listing does not establish treatment availability, FDA approval or permission to promote.

03 · Product-specific private publisher review

Liraglutide

Liraglutide has product-specific U.S. prescribing information. A named approved medicine does not make every preparation, indication or marketing claim equivalent. The private brief must identify the actual product and service.

View publisher information →

05 · Product-specific private publisher review

PT-141 (Bremelanotide)

PT-141 is listed here with the requested bremelanotide name. Vyleesi prescribing information concerns a specific bremelanotide product and use; it does not establish approval for every product marketed as PT-141.

View publisher information →

07 · Investigational information — no treatment offer

Cagrilintide

Cagrilintide is an investigational topic. This page presents research-status information, not an available treatment-referral offer. Keep a single candidate separate from the CagriSema combination.

View publisher information →

08 · Investigational information — no treatment offer

CagriSema

Novo Nordisk describes CagriSema as an investigational combination of cagrilintide and semaglutide. It is not the same entry as semaglutide alone or cagrilintide alone. This page does not present an available treatment offer.

View publisher information →

09 · Investigational information — no treatment offer

Survodutide

Survodutide is covered as a clinical-development topic. Sponsor trial reporting does not establish a current MarketHealth treatment campaign or permission to promote the candidate to patients.

View publisher information →

10 · Investigational information — no treatment offer

Pemvidutide

Altimmune identifies pemvidutide as investigational. This resource explains publisher coverage boundaries and does not advertise an approved product, a consumer purchase or an available treatment-referral campaign.

View publisher information →

11 · Investigational information — no treatment offer

VK2735

VK2735 is covered under its development code. A sponsor’s clinical-program announcement is not evidence of an approved medicine or an open treatment-referral offer. Keep the candidate distinct from approved products.

View publisher information →

12 · Investigational information — no treatment offer

Amycretin (Zenagamtide)

Novo Nordisk uses zenagamtide for the candidate formerly known as amycretin. These names share one information entry here. The candidate is covered as a development topic, not an available treatment-referral campaign.

View publisher information →

16 · Publisher-review information

CJC-1295 with DAC

This entry preserves the explicit “with DAC” qualifier. It is separate from Modified GRF 1-29 and from the generic CJC-1295 topic. The exact advertiser preparation must be identified before any product or campaign description is approved.

View publisher information →

19 · Publisher-review information

AOD-9604

AOD-9604 has its own publisher-review entry. Interest in the name does not establish an approved weight-management indication or a currently permissible preparation. The proposed product and campaign need their own documentation.

View publisher information →

20 · Publisher-review information

Thymosin Alpha-1

Thymosin Alpha-1 is kept separate from TB-500 and other thymosin-related names. This page makes no immune-treatment claim and does not infer campaign eligibility from a related substance or a historical list change.

View publisher information →

21 · Publisher-review information

Epitalon

Epitalon is a distinct publisher-review topic. A longevity-oriented search or campaign nickname does not substantiate a lifespan, age-reversal or clinical-treatment promise. Any proposed description must match a reviewed preparation.

View publisher information →

23 · Publisher-review information

KPV

KPV is retained as a separate requested topic. A short sequence or abbreviation does not establish product identity, route, permissible marketing or a treatment indication. The campaign brief must resolve those details.

View publisher information →

24 · Publisher-review information

DSIP

DSIP is listed as its own publisher-review topic. The abbreviation must not become a promise about sleep, sedation or treatment. Obtain the actual substance and proposed preparation before evaluating a campaign.

View publisher information →

25 · Publisher-review information

Selank

Selank inquiries require an exact product record. Do not treat an alternate formulation or salt as automatically interchangeable, or turn a topic listing into an anxiety-treatment or cognitive-performance claim.

View publisher information →

26 · Publisher-review information

Semax

Semax has a separate information page from Selank. Similar audience interest does not make two named substances equivalent or establish a permissible cognitive or neurological treatment campaign.

View publisher information →

27 · Publisher-review information

GHRP-2

GHRP-2 and GHRP-6 remain separate entries. Do not infer equivalent formulations, campaign terms or performance claims from the shared GHRP naming pattern. The actual proposed preparation must be reviewed.

View publisher information →

28 · Publisher-review information

GHRP-6

GHRP-6 is not combined with GHRP-2 in this directory. A related name does not establish the same product, clinical scope or publisher permissions. Review its own documentation before developing a campaign.

View publisher information →

CJC-1295 with DAC and Modified GRF 1-29 are separate entries. Amycretin and Zenagamtide share one identity entry. Blend names do not establish ingredients or an approved indication.

Telehealth publisher signup & requirements